# A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

> **NCT02914938** · PHASE1 · TERMINATED · sponsor: **MEI Pharma, Inc.** · enrollment: 97 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Follicular Lymphoma (FL)
- Marginal Zone B Cell Lymphoma
- Diffuse Large B-cell Lymphoma (DLBCL)
- High Grade Non-Hodgkin's Lymphoma
- Mantle Cell Lymphoma (MCL)

## Interventions

- **DRUG:** ME-401
- **DRUG:** Rituximab
- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT02914938
- **Lead sponsor:** MEI Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10
- **Primary completion:** 2023-03-29
- **Final completion:** 2023-03-29
- **Target enrollment:** 97 (ACTUAL)
- **Why stopped:** discontinuation of zandelisib program
- **Last updated:** 2023-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02914938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02914938, "A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02914938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*